期刊文献+

教育和管理干预对腹膜透析患者高磷血症控制的影响 被引量:1

Effects of education and management intervention onhyperphosphatemia control of peritoneal dialysis patients
下载PDF
导出
摘要 目的:探讨教育和管理干预对腹膜透析患者高磷血症控制的影响。方法:选择2014年1~12月在我院肾内科规律腹膜透析的188例患者和25位名护人员作为研究对象,应用教育和管理的措施实施干预,比较干预前后患者的高磷血症知识、自我管理能力、血磷水平以及医护人员高磷血症知识知晓情况的差异。结果:经教育和管理干预后患者髙磷血症知识、自我管理能力提高了,血磷水平下降,前后比较差异有统计学意义(P〈0.05)。医护人员高磷知识得分也提高了,前后比较有统计学意义(P〈0.05)。结论:为腹膜透析患者提供教育和管理干预能帮助其降低血磷值或预防血磷值升高。 Objective: To discuss Effects of education and management intervention on hyperphosphatemia control of peritoneal dialysis patients. Methods:Selected 188 cases of peritoneal dialysis patients cured in nephrology department of our hospital from January to December in 2014,and 25 medical staff as study objects. Implemented intervention with education and management measures and found out differences before and after the intervention by comparison.Results: After education and management intervention,patients had improved hyperphosphatemia knowledge and self- management ability,and lower serum phosphorus. The differences before and after the intervention had statistical significance( P〈 0. 05). Conclusion: To provide education and management intervention to peritoneal dialysis patients can help them to decrease and prevent rise of serum phosphorus.
出处 《护理实践与研究》 2016年第10期26-27,共2页 Nursing Practice and Research
关键词 腹膜透析 教育 管理干预 高磷血症 Peritoneal dialysis Education Management intervention Hyperphosphatemia
  • 相关文献

参考文献6

二级参考文献72

  • 1钱家麒.腹膜透析中需要关注的几个问题[J].中华肾脏病杂志,2005,21(5):240-241. 被引量:11
  • 2<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97
  • 3Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure [Jj. Am J Kidney Dis, 2001,37(Suppl 2) : S66 - S70.
  • 4Blake PG, Bargman JM, Bick J, et al. Guidelines for adequacy and nutrition in peritoneal dialysis[ J]. J Am Soc Nephrol, 1999,10:S287 - S321.
  • 5Wei M, Taskapan H, Esbaei K, et al. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? [ J]. Int Urol Nephrol, 20136,38(3-4) : 739-743.
  • 6National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney diseaseE J~. Am J Kidney Dis, 2003,42( Suppl 3): S 1-S201.
  • 7Habib AN, Baird BC, Leypoldt JK, et al. The association of lipid levels with mortality in patients on chronic peritoneal dialysis[J]. Erol Dial Transplant, 2006,21 (10) : 2881 - 2892.
  • 8Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism dismrbanees and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease[J]. Nephrol Dial Transplant, 2009,24(5) : 1358 - 1361.
  • 9Dong J, Wang H, Wang M. Low prevalence of hyper- phosphatemia independent of residual renal function in peritoneal dialysis patients [ J ]. J Renal Nutr, 2007,17 (6) : 389 -396.
  • 10Chen HY, Kao TW, Huang JW, et al. Association between dyslipidemia and residual renal function in patients on chronic peritoneal dialysis [ J ]. Clin Nephrol, 2008,70(2) : 233 - 239.

共引文献69

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部